The weekly litigation news digest is live. Subscribe now
Dulaglutide For The Treatment Of Chronic Kidney Disease - EP3630164
The patent EP3630164 was granted to ELI Lilly on Aug 23, 2023. The application was originally filed on May 24, 2018 under application number EP18730908A. The patent is currently recorded with a legal status of "Granted And Under Opposition".
EP3630164
- Application Number
- EP18730908A
- Filing Date
- May 24, 2018
- Status
- Granted And Under Opposition
- Jul 21, 2023
- Publication Date
- Aug 23, 2023
- External Links
- Slate, Register, Google Patents
Patent Summary
Dulaglutide, a GLP-1R agonist, provides sustained and rapid attenuation of kidney disease progression in patients with stage 2-4 CKD. By targeting the GLP-1 receptor pathway, dulaglutide improves glycemic control, but its therapeutic effects extend beyond glycemic management. The treatment achieves significant renal function preservation, with a median time to renal death of 26 weeks compared to existing therapies, and cardiovascular benefits. Dulaglutide's mechanism of action enables sustained therapeutic effects beyond glycemic control, offering a novel treatment option for patients with CKD stage 2 or worse.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Patent Citations (3) New
Patent citations refer to prior patents cited during different phases such as opposition or international search.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents